Abstract
We monitored antimicrobial susceptibility developments of Neisseria gonorrhoeae in Germany from January 2014 to May 2021. The proportion of isolates with azithromycin minimum inhibitory concentrations above the epidemiological cut-off increased substantially, from 1.3% in 2014 to 12.2% in 2020. Preliminary data from 2021 showed a further rise (January to May: 20.7%). Therefore, azithromycin as part of the recommended dual therapy in Germany for non-adherent patients is challenged. Antimicrobial susceptibility testing in clinical practice is crucial and continuous susceptibility surveillance indispensable.
Highlights
We monitored antimicrobial susceptibility developments of Neisseria gonorrhoeae in Germany from January 2014 to May 2021
Looking at the minimum inhibitory concentrations (MIC) values in detail (Figure 2), we found a noticeable population of isolates with MIC in the range of 0.38–1 mg/mL for the years 2014 and 2015
We found a marked increase in the proportion of isolates in the category above the epidemiological cut-off (ECOFF) with MIC values between 1.5 and 4 mg/L during the entire period studied (Table); this distribution was statistically significant (Spearman’s rho: p = 0.02)
Summary
Citation style for this article: Selb Regina, Buder Susanne, Dudareva Sandra, Tamminga Thalea, Bremer Viviane, Banhart Sebastian, Heuer Dagmar, Jansen Klaus. Decreasing azithromycin susceptibility of Neisseria gonorrhoeae, Germany, 2014 to 2021. Article submitted on 18 Jun 2021 / accepted on 03 Aug 2021 / published on 05 Aug 2021. We monitored antimicrobial susceptibility developments of Neisseria gonorrhoeae in Germany from January 2014 to May 2021. The German national surveillance system on Neisseria gonorrhoeae (NG)-antimicrobial resistance (AMR) has been in place at the Robert Koch Institute (RKI) since 2014 [1]. Using susceptibility data of NG, we monitored the dynamics of the proportions of resistant isolates and of minimum inhibitory concentrations (MIC) in Germany from January 2014 to May 2021 to inform treatment guidelines
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
